Urinary bladder outlet obstruction results in sustained stretch of the detrusor muscle and can lead to pathological smooth muscle hyperplasia and hypertrophy. The epidermal growth factor receptor (EGFR) is a cognate receptor for mitogens implicated in bladder hyperplasia/hypertrophy. Here, we investigated the potential for modulation of this pathway by pharmacologic targeting with a clinically available EGFR antagonist using an organ culture model of bladder stretch injury as a test system. Urinary bladders from adult female rats were distended in vivo with medium containing the EGFR inhibitor ZD1839 (gefitinib, Iressa). The bladders were excised and incubated in ex vivo organ culture for 4-24 h. EGFR phosphorylation, DNA proliferation, and the extent of apoptosis in the cultured tissues were assessed. To verify that the smooth muscle cells (SMC) are a target of the EGFR inhibitor, primary culture human and rat bladder SMC were subjected to cyclic mechanical stretch in vitro in the presence of ZD1839. Levels of phosphorylated EGFR were significantly increased in the detrusor muscle with 12 h of stretch in the organ cultures. This activation coincided with a subsequent 23-fold increase in DNA synthesis and a 30-fold decrease in apoptosis in the muscle compartment at 24 h. In the presence of ZD1839, DNA synthesis was reduced to basal levels without an increase in the rate of apoptosis under ex vivo conditions. Mechanical stretch of bladder SMC in vitro resulted in a significant increase in DNA synthesis, which was completely abrogated by treatment with ZD1839 but not by AG825, an inhibitor of the related receptor, ErbB2. Our results indicate that the EGFR pathway is a physiologically relevant signaling mechanism in hypertrophic bladder disease resulting from mechanical distension and may be amenable to pharmacologic intervention.
Urinary bladder outlet obstruction can result from a variety of anatomical and/or functional abnormalities of the genitourinary system. The opposing physiologic roles of the bladder, prolonged storage of urine under low pressure and acute contraction during urination, are tightly regulated and coordinated such that they occur cooperatively, with the normal bladder emptying completely with voiding. Obstruction of the bladder outlet generates increased contractile forces during the contraction phase, and also results in incomplete emptying. This condition elicits chronic overdistention (sustained stretch of the tissue) and triggers pathologic remodeling of the bladder wall. Prolonged bladder outlet obstruction results in a fibroproliferative reaction characterized by smooth muscle cell (SMC) hyperplasia/hypertrophy and extracellular matrix deposition. 1, 2 The role of sustained stretch as a discrete stimulus is thought to represent a major contributing factor to the tissue changes seen with obstruction. 1, 3 The ability of a mechanical stimulus to trigger cell growth has been observed in several systems, including vascular SMC, [4] [5] [6] cardiac myocytes, 7, 8 and epithelial cells. [9] [10] [11] [12] Growth factors and other signaling proteins regulate diverse cellular functions, including responses to changing physiological conditions. Adaptation to sustained stretch may initially be protective-that is, expansion of the smooth muscle compartment as an adaptive response to augment bladder emptying-but over time such changes can become deleterious. Cell growth responses, such as those observed in SMC hyperplasia and hypertrophy, are partly the result of the action of soluble mitogens. 13 The downstream targets of these factors provide potential regulatable targets for therapies aimed at modulating aberrant cellular processes.
Growth regulatory proteins whose expression is affected by mechanical forces have been implicated in the response of SMC to tension and pressure. [14] [15] [16] [17] [18] The gene encoding heparin-binding epidermal growth factor-like growth factor (HB-EGF) was identified as stretch-and pressure-responsive in bladder SMC. 15, 17 HB-EGF signals principally through the transmembrane receptor tyrosine kinase (RTK) epidermal growth factor receptor (EGFR, ErbB1), which activates a number of well known signal transduction pathways. 19 Stretch of bladder SMC in vitro leads to increased DNA synthesis as well as rapid activation of multiple signaling cascades. 20 Studies on HB-EGF in the urinary tract have suggested a role for the activated EGFR in compensatory bladder hyperplasia and hypertrophy. Some of the evidence for this hypothesis is the following: (1) bladder SMC is a site of HB-EGF synthesis; 21, 22 (2) HB-EGF expression is stretchresponsive in bladder SMC in vitro and in vivo; 15, 22, 23 (3) HB-EGF is a bladder SMC mitogen; 21 and (4) bladder SMC express the EGFR. 22 In addition, the EGFR has been implicated in stretchinduced growth and proliferation of other hollow organs and structures such as the cardiovascular system, [5] [6] [7] [24] [25] [26] [27] lung tissue, 11 renal tubules, 9 and the gastrointestinal tract. 28 In this study, we tested whether (1) controlled distension of the intact urinary bladder in ex vivo organ culture, and of primary culture bladder SMC in vitro, results in EGFR activation and (2) whether pharmacologic blockade of this receptor, using a well-characterized inhibitor, alters the cellular response to the pathologic stimulus. Our results show that downstream effects of the sustained stretch stimulus were attenuated by the pharmacologic blockage regimen, suggesting that the EGFR plays an important role in stretch-induced urinary bladder SMC hyperplasia and hypertrophy. Moreover, such antagonists may have therapeutic benefit in the context of bladder outlet obstruction as a means to protect the tissue from decompensation.
Methods
All animal experiments were performed and human tissues obtained with approval from the Institutional Animal Care and Use Committee and Institutional Review Board, respectively, at Children's Hospital Boston.
Ex Vivo Model of Bladder Overdistention
An ex vivo model of bladder stretch injury was used as previously described. 23 Briefly, 30-day-old-female Wistar rats were anesthetized with isoflurane inhalation. The bladder was catheterized and drained via a 20-gauge intravenous catheter. A low midline incision was made to expose the bladder, and the ureters were ligated and divided. The bladder neck was isolated and surrounded by a 4-0 silk suture. The bladder was then stretched to 40 cm water pressure using a gravity manometer with medium optimized for maintenance of the urothelium (modified keratinocyte growth medium (KGM) supplemented with 2% fetal bovine serum (FBS)). 29 The bladder neck suture was then tightened, the catheter removed, and the bladder excised and placed in Dulbecco's modification of Eagle's medium (DMEM) supplemented with 10% FBS. Bladders were maintained in culture for 4, 12, 18, and 24 h in a humidified 5% CO 2 /95% air atmosphere incubator. As a control, a nonstretched bladder for each time point was harvested and incubated in the identical fashion as the stretched bladders. Four bladders were employed for each time point and each condition (nonstretched and stretched).
In Vitro Cyclic-Stretch Relaxation of Bladder Smooth Muscle Cells
Primary culture human and rat bladder SMC were obtained as described previously, 15, 30 and maintained in DMEM/10% FBS, or medium 199 (M199)/20% FBS, respectively. Cells were routinely cultured at 371C, 5% CO 2 /95% air in a humidified incubator. Cells were subjected to cyclic-stretch relaxation and 3 H-thymidine incorporation was assessed essentially as described. 15 Briefly, cells were serum-depleted for 24 h and then stretched for 12 h, 18 h, and 24 h (20% elongation, 0.1 Hz). For the final 8 h of stretch, 0.5 mCi/well 3 H-thymidine was added, and incorporation of radioactivity into acidprecipitable material was measured by scintillation counting. Nonstretched cells that were seeded and incubated in parallel served as controls. In selected wells, cells were incubated with the EGFR-specific tyrosine kinase inhibitor (TKI) ZD1839 (10 mM) or the ErbB2-specific inhibitor AG825 (Calbiochem, San Diego, CA, USA) (0.35 mM) for 30 min before initiation of stretch.
Preparation of Whole-Bladder Tissue Lysates
Tissue from replicate bladders at each time point was combined and placed in 0. 5 
Immunohistochemical Analyses
Bladder tissue was fixed with 10% neutral buffered formalin at room temperature for 8 h, washed with phosphate buffered saline (PBS), and dehydrated with ethanol gradient washes. Tissue was then paraffin embedded and 8 mm sections were obtained using a microtome. The sections were mounted on glass slides and baked for 30 min at 701C. Sections were deparaffinized and rehydrated using xylene and gradient ethanol washes. Endogenous peroxidase activity was neutralized by incubation in 3% hydrogen peroxide for 15 min. Sections were washed with either PBS or Tris-buffered saline (TBS) depending on antibody and manufacturer's recommendations. Antibodies included anti-EGFR (Santa Cruz), antiphospho-EGFR (Tyr 1068, Cell Signaling), anti-ErbB2 (Upstate Cell Signaling Solutions, Waltham, MA, USA), antiphospho-erbB2 (Cell Signaling), anti-ErbB3 (Santa Cruz), and anti-ErbB4 (Cell Signaling). All sections were incubated in primary antibody overnight at 41C. Appropriate biotinylated secondary antibodies were utilized and antigen-antibody complexes visualized with the avidin-biotin complex (ABC) method (Vector Laboratories, Burlingame, CA, USA). All experiments included negative controls consisting of sections incubated with secondary antibody only. Immunohistochemical staining was examined under brightfield microscopy (Zeiss Axioplan, Carl Zeiss, Thornwood, NY, USA). Stain intensity was quantitated using image analysis (Image J, NIH). Hematoxylin and eosin and Masson's trichrome staining revealed minimal changes in bladder tissue architecture in response to distention, with both the urothelium and SMC compartments remaining intact for at least 24 h in culture (data not shown).
5-Bromo2
0 -deoxyuridine and TUNEL Staining
To measure the extent of DNA synthesis in bladders cultured ex vivo, organs were decompressed and incubated with 5-bromo2 0 -deoxyuridine (BrdU, 10 mM) for 3 h at 371C in a 5% CO 2 /95% air humidified incubator. BrdU was diluted in serumfree M199 medium before addition to tissue. Following incubation, bladders were bisected transversely; one half was used for isolation of protein and the other was fixed in formalin and embedded in paraffin. Paraffin-embedded samples were sectioned and prepared for immunohistochemistry (IHC) as described above. BrdU incorporation was detected by alkaline-phosphatase-based IHC (Roche Applied Science) per manufacturer's protocol and was visualized under brightfield microscopy. A section of rat ileum served as a positive control with each set of experiments. A section incubated with secondary antibody only served as a negative control. BrdU-positive nuclei were quantified by automated counting performed by image analysis software (Image J, NIH) on 3 high power fields from 3 different sections.
The degree of apoptosis was assessed by terminal deoxynucleotidyl transferase biotin-dUTP nick end labeling (TUNEL) staining. Paraffin-embedded samples were sectioned and prepared for IHC as described above. TUNEL staining was detected by peroxidase-based IHC using the In Situ Cell Death Detection Kit (Roche Applied Science) per manufacturer's protocol and visualized under brightfield microscopy. Positive controls were created by treating bladder sections with DNAse I (Roche Applied Science) and proteinase K (Roche Applied Science) for 30 min at 371C. A section incubated with secondary antibody only served as a negative control. TUNEL-positive nuclei were quantified by automated counting performed by image analysis software (Image J, NIH) on 3 high power fields from 3 different sections.
Pharmacologic Inhibition of ErbB-Dependent Signaling
In selected experiments, we employed the EGFRspecific 31 TKI, ZD1839 (Gefitinib, Iressa, obtained from AstraZeneca, Cheshire, UK) to achieve pharmacologic blockade of EGFR-dependent signaling in bladder cells and tissue. ZD1839 was reconstituted with DMSO to a stock concentration of 20 mM. In preliminary experiments, NRK-52E cells were treated with rEGF (100 ng/ml) in the presence of increasing doses (0.01-50 mM) of ZD1839. Whole-cell lysates were subjected to SDS-PAGE and immunoblotting with antibody against phospho-EGFR (Tyr 1068, CST). Alternatively, primary bladder SMC were subjected to cyclic-stretch relaxation in the absence or presence of the indicated doses of ZD1839 or the ErbB2 inhibitor AG825. Drugs were added to cells 30 min before initiation of stretch, and thymidine incorporation was determined as described above. Based on these data whole bladders were treated with 10 mM ZD1839 in the following ways: (1) in the media surrounding the bladder (extraluminal); or (2) in the media surrounding and the media within the lumen of the bladder (extra-and intraluminal); or (3) in the media within the lumen of the bladder (intraluminal). Specimens were subjected to sustained mechanical stretch as described above. Bladders that were not stretched and bladders that were stretched but not treated with ZD1839 served as controls for each experiment. Each time point was repeated in triplicate. Following experimental manipulation, specimens were treated with BrdU and processed for BrdU and TUNEL staining, or IHC for total and phosphorylated forms of the EGFR or the related receptor ErbB2, as described above.
Statistical Analysis
Using commercially available software (SPSS 14.0, Chicago, IL, USA), the one-way ANOVA procedure was used to test for variance among multiple comparison groups, and Tukey's test utilized for statistical significance. A P-value of less than 0.05 was considered significant.
Results
Previous data from our laboratory demonstrated expression of the EGFR/ErbB1 in the smooth muscle compartment of human and mouse bladder. 22 To determine whether EGFR activation occurs in situ in response to bladder wall distension, we employed an ex vivo model of bladder stretch as described previously.
3 This model has advantages over in vivo outlet obstruction in that systemic effects not of bladder origin are eliminated and early consequences of the distension stimulus can be monitored before gross and irreversible fibroproliferative remodeling.
Bladders were distended in vivo to 40 cm H 2 O using water manometry and incubated ex vivo under standard cell culture conditions for 4 h, 12 h, 18 h, and 24 h. This pressure was selected because it is known to be a pathologically elevated urinary storage pressure associated with upper urinary tract deterioration. 32 Expression and activation status of the EGFR was determined by IHC analysis using antibodies to total and phosphorylated EGFR. At all time points studied, the EGFR was expressed in bladder SMC and was localized predominantly to the cytosol (Figure 1) . Preincubation of anti-EGFR antibody with blocking peptide abolished EGFR staining, confirming the specificity of the antibody for EGFR (not shown
Next, we determined the extent of DNA synthesis and apoptosis in whole bladders by BrdU labeling and TUNEL staining, respectively. BrdU incorporation increased 23-fold in distended tissue at 18 h and 24 h compared to undistended controls (Po0.001) (Figure 2 ). In contrast, there was a 30-fold increase in TUNEL staining at 4 h of stretch (Po0.001), but a reduction to a B5-fold difference between distended and undistended specimens at 24 h (Figure 2 ). These observations indicate that sustained distension results in increased apoptosis at 4 h and increased cell proliferation 18-24 h.
To examine the relationship between EGFR activation and cellular events triggered by the sustained stretch injury, we employed the EGFR TKI, ZD1839, to attenuate EGFR-dependent signals. To assess whether mechanical stretch-induced cell cycle transit could be affected by the EGFR inhibitor in bladder SMC, primary culture rat and human bladder SMC were subjected to cyclic stretchrelaxation in vitro in the absence or presence of ZD1839 or the ErbB2-specific inhibitor, AG825. DNA synthesis rate was determined by uptake of 3 H-thymidine. 15 As shown in Figure 3 , stretchinduced DNA synthesis in both rat and human BSMC, consistent with previous reports. Treatment with ZD1839 significantly inhibited stretch-induced DNA synthesis at both 12 and 24 h (Po0.0001), whereas AG825 had no measurable effect on DNA synthesis.
To assess potential effects of the drugs in whole tissue, rat bladders were distended ex vivo in the absence or presence of 10 mM ZD1839 administered: (a) intraluminally only (inside); (b) intraluminally and in the external culture medium (inside and outside); or (c) only in the external culture medium (outside). Regardless of the route of administration of drug, ZD1839 abrogated EGFR phosphorylation by greater than 70% (Figure 4 ). The decrease in staining intensity for the phosphospecific EGFR antibody was statistically significant (Po0.01) for all three conditions when compared to untreated specimens (Figure 4) , with no significant difference in the extent of EGFR inhibition between addition of the drug in the bladder lumen or in the external medium (not shown).
The effect of EGFR blockade on proliferation and apoptosis was determined by BrdU labeling and TUNEL staining of ZD1839-treated stretched bladder tissue. At 18 and 24 h, intraluminal treatment with ZD1839 reduced BrdU incorporation by approximately 40% (Po0.001) ( Figure 5 ), whereas TUNEL staining revealed no detectable apoptosis in response to drug treatment. These data suggest that ZD1839 attenuates distensioninduced bladder SMC proliferation by effects on cell cycle progression, as opposed to induction of cell death.
Discussion
Mechanical stretch is a well-described proliferative stimulus in diverse cell types including vascular and urinary bladder SMC, cardiac myocytes, and epithelial cells. 1, 3, 4, [8] [9] [10] [11] [12] 15, 23, 33 Stretch results in the elaboration of a variety of soluble growth factors, a process that appears to be cell-and physiologic context-dependent, and the EGFR has been described as an important receptor for stretch-induced factors in various tissues. [5] [6] [7] [9] [10] [11] [12] [24] [25] [26] [27] [28] In urinary bladder SMC, stretch induces the HB-EGF gene and protein. HB-EGF is a well-known SMC mitogen 21, 23, 34 and ligand for the EGFR. 22 The results presented here indicate that the EGFR mediates SMC growth in situ in the urinary bladder in response to distension arising from a physiologically relevant stimulus. We have also shown that pharmacologic inhibition of EGFR signaling abrogates stretch-induced SMC proliferation.
Previous studies have implicated signaling though the ErbB receptor-ligand axis in hypertrophic growth of bladder SMC exposed to mechanical stimuli. 20, 22, 35 The EGFR, ErbB2, and ErbB3 are expressed in the human and murine urinary bladder, 22 and stretch of bladder SMC in vitro leads to increased DNA synthesis as well as rapid activation of multiple signaling cascades. 20, 33 Notably, transient stretch (10 min) of bladder SMC in vitro has been reported to stimulate phosphorylation of ErbB2 but not the EGFR. 20 In the present study, we observed phosphorylation only of the EGFR, but not ErbB2, following 12 h of sustained mechanical stretch of the intact bladder ex vivo, suggesting that signaling via these related receptors is dependent on the duration of the physiologic stimulus. We also observed a significant increase in DNA synthesis in intact specimens following 18 h and 24 h of sustained distention and in primary culture SMC following 24 h of cyclic stretch-relaxation in vitro. Net proliferation of bladder SMC in the ex vivo Primary culture human BSMC were subjected to cyclic stretch-relaxation for 12 and 24 h, in the absence or presence of either 10 mM ZD1839 (ZD) or 0.35 mM AG825 (AG). Cells treated with DMSO vehicle (V) served as control. 0.5 mCi/well 3 H-thymidine was added during the final 8 h of stretch, and the extent of DNA synthesis was determined by measurement of 3 H-thymidine incorporation into acid-precipitable material. Experiments were performed in triplicate, and data are presented as mean7s.d. Significant values (Po0.05) are indicated (*). Treatment with ZD1839 significantly inhibited stretch-induced DNA synthesis at both 12 and 24 h (Po0.001), whereas AG825 had no measurable effect on DNA synthesis. Inset: Primary culture rat BSMC were tested as above. Shown are data from 24 h stretch, demonstrating the efficacy of ZD1839 in attenuating stretch-induced DNA synthesis (Po0.001). NS, nonstretched; S, stretched. model system was accompanied by a significant reduction in the rate of apoptosis by 24 h of distension, after increasing nearly 30-fold above baseline at the 4 h time point. Our findings are in agreement with those reported by Galvin et al 33 who demonstrated that in vitro bladder SMC apoptosis peaks following 3 h of stretch and is significantly diminished following 24 h of stretch. They concluded that mechanical stretch regulates proliferation and apoptosis in the urinary bladder and suggested that stretch may be an antiapoptotic stimulus in SMC. Our results appear to support their conclusions.
We selected the ex vivo whole-organ culture system to model sustained bladder stretch associated with outlet obstruction because it provides a means to precisely separate and isolate the tensional forces involved in bladder filling from those involved in contraction. It also maintains the complex cell matrix context of the intact organ, allows isolation of the intact organ from systemic humoral and neurological influences, and provides direct access for putative therapeutic agents. 3 We have previously demonstrated that findings on stretchinduced gene expression using in vitro cell culture could be replicated in the ex vivo organ culture system. 23 In addition, in the modeling of urinary bladder outlet obstruction, the sustained distension evoked in our ex vivo whole-organ culture model may represent a more accurate representation of the pathological stimulus rather than brief periods of rapid cellular deformation utilized in in vitro systems.
EGFR signaling has been studied in several ex vivo organ culture models, including the cornea, 36 intestinal tissue, 28, 37 facial tissue, 38 skin, 39 lung, 40 and vasculature. 5, 6, 24 In several studies, pharmacologic inhibitors have been used to modulate the EGFR signaling cascade in the whole organ. 6, 28, 36, 37, 39 In this study, we utilized the EGFR TKI ZD1839 (gefitinib, Iressa) to assess the relationship between distension-stimulated EGFR phosphorylation and DNA synthesis in the intact bladder. The selectivity of ZD1839 for EGFR tyrosine kinases over its closely related proteins (Erb2, Erb3, Erb4) has been previously demonstrated, 31 and was a primary rationale for the study reported here. To model its potential use as an intravesical vs systemic therapeutic agent, ZD1839 was tested both as an intraluminal (intravesical) and/or extraluminal (extravesical) agent. In ZD1839-treated specimens, EGFR phosphorylation and DNA synthesis were significantly reduced and approached baseline levels. Inhibition of DNA synthesis in bladder muscle ex vivo was not associated with an increase in the apoptotic rate, suggesting that the biological effect of ZD1839 was not due simply to generalized toxicity. Interestingly, ZD1839 delivered directly into the bladder lumen was as effective at inhibiting stretch-stimulated DNA synthesis in bladder SMC as administering the drug both inside and outside the bladder. Although ZD1839 has been used most widely as systemic anticancer therapy, our findings suggest that this and other EGFR-targeted TKIs may have clinical utility for the localized, that is, intravesical, treatment of urologic disease characterized by SMC hyperplasia and hypertrophy. In addition, our results were supported by our in vitro experiments, which demonstrated that only EGFR and not ErbB2 inhibition significantly abrogated DNA synthesis following sustained mechanical stretch. The demonstration in this study that ZD1839 can interfere with EGFR-dependent signals in bladder SMC suggests that a similar strategy would be effective in modulating EGFR activation in other hollow organs that display aberrant SMC proliferation.
The inhibition of SMC proliferation in response to stretch must be examined, however, in a physiological context. Unanticipated smooth muscle growth in the bladder is usually an adaptive response to generate increased evacuative force to overcome outlet resistance, or a result of neuromuscular overdrive. In some situations (eg, outlet resistance) the growth response is compensatory, allowing the bladder to temporize urinary evacuation. Thus, illtimed antiproliferative muscle therapy, may, in fact be clinically undesirable. Ideally, early recognition or prevention of the inciting factors would prevent muscle overgrowth. Until this becomes possible, the outcome is usually a progressive and maladaptive muscle wall thickening, which often persists despite ultimate treatment of the primary insults. While our study represents one possible avenue to management of muscle overgrowth, the issue of timing of treatment and selection of which bladders are best suited and destined to respond to antiproliferative strategies will require further study.
In summary, we demonstrate (1) that a functional EGFR-dependent signaling mechanism is present in the urinary bladder, (2) that it is required for mechanical stretch-stimulated SMC proliferation, and (3) that pharmacologic inhibition of EGFR signaling abrogates stretch-induced SMC proliferation. This was demonstrated using an ex vivo whole-organ culture system, an in vitro cyclic stretch model using rodent and human BSMC, and a specific EGFR TKI in both settings. The consistency of our findings across model platforms and species suggests that the EGFR may represent a critical and modulatable component of bladder SMC response to sustained stretch injury. Further investigation in vivo may lead to a potentially novel intravesical therapeutic strategy for limiting deleterious bladder SMC hyperplasia and hypertrophy in patients with diseases characterized by chronic muscle deformation and contraction.
